The US Alzheimer’s diagnosis and drugs market is witnessing growth due to the rising prevalence of Alzheimer’s disease, increasing emphasis on early diagnosis, and continued development of disease-modifying therapies. Advances in blood-based biomarkers, neuroimaging, and cognitive assessment are improving diagnostic capabilities, while newer therapeutic approaches, including...